SAFETY AND EFFICACY OF VANDETANIB AS SYSTEMIC TREATMENT FOR PATIENTS WITH ADVANCED AND PROGRESSIVE MEDULLARY THYROID CANCER (MTC)

被引：0

作者：

Grande, E. ^{[1
]}

Martinez-Trufero, J. ^{[2
]}

Arevalo, S. ^{[3
]}

Alvarez-Escola, C. ^{[4
]}

Beltran, M. ^{[5
]}

Jimenez Fonseca, P. ^{[6
]}

Alonso-Gordoa, T. ^{[1
]}

Dalmau, E. ^{[7
]}

Duran, M. ^{[8
]}

Gallegos, I. ^{[9
]}

Manzano, J. L. ^{[10
]}

Mesia, R. ^{[11
]}

Pajares, I. ^{[12
]}

Fuentes, J. ^{[13
]}

Grau, J. J. ^{[14
]}

Reig Torras, O. ^{[14
]}

Trigo, J. M. ^{[15
]}

Pelaez, B. ^{[16
]}

Zafon, C. ^{[17
]}

Capdevila, J. ^{[18
]}

机构：

[1] Ramon & Cajal Univ Hosp, Med Oncol Dept, Madrid, Spain

[2] HU Miguel Servet, Zaragoza, Spain

[3] Hosp Donostia, Med Oncol Dept, San Sebastian, Spain

[4] La Paz Univ Hosp, Dept Endocrinol, Madrid, Spain

[5] ICO Girona, Girona, Spain

[6] Hosp Univ Cent Asturias, Serv Oncol Med, Oviedo, Spain

[7] Corp Hosp Parc Tauli, Sabadell, Spain

[8] Hosp Rey Juan Carlos, Mostoles, Spain

[9] Hosp Gen Segovia, Serv Oncol Med, Segovia, Spain

[10] ICO Hosp Germans Trias & Pujol, Barcelona, Spain

[11] Inst Catala Oncol ICO Hosp, IDIBELL Head & Neck Canc Unit, Med Oncol Dept, Barcelona, Spain

[12] Hosp Clin Lozano Blesa, Zaragoza, Spain

[13] Hosp Valme, Seville, Spain

[14] Hosp Clin Barcelona, Barcelona, Spain

[15] Hosp Univ Virgen de la Victoria, Malaga, Spain

[16] Univ Hosptial Valladolid, Valladolid, Spain

[17] Vall de Hebron Univ Hosp, Endocrinol Dept, Barcelona, Spain

[18] Vall dHebron Univ Hosp, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2014年 / 25卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1161P

引用

页数：1

共 50 条

[21] Predictive value of FDG-PET in patients with advanced medullary thyroid cancer undergoing vandetanib treatment
Werner, Rudolf
Higuchi, Takahiro
Muegge, Dirk
Javadi, Mehrbod
Fassnacht, Martin
Buck, Andreas
Lapa, Constantin
Kreissl, Michael
JOURNAL OF NUCLEAR MEDICINE, 2017, 58
[22] The safety of vandetanib for the treatment of thyroid cancer
Tsang, Venessa H. M.
Robinson, Bruce G.
Learoyd, Diana L.
EXPERT OPINION ON DRUG SAFETY, 2016, 15 (08) : 1107 - 1113
[23] Vandetanib—a new therapeutic option in advanced medullary thyroid cancer
Linda Koch
Nature Reviews Endocrinology, 2012, 8 (1) : 1 - 1
[24] Vandetanib: A Guide to Its Use in Advanced Medullary Thyroid Cancer
Keating, Gillian M.
Lyseng-Williamson, Katherine A.
Frampton, James E.
BIODRUGS, 2012, 26 (06) : 431 - 435
[25] Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer
Bastholt, Lars
Kreissl, Michael C.
Fuehrer, Dagmar
Maia, Ana L.
Locati, Laura D.
Maciel, Lea
Wu, Yi
Heller, Kevin N.
Webster, Alan
Elisei, Rossella
EUROPEAN THYROID JOURNAL, 2016, 5 (03) : 187 - 194
[26] Vandetanib: A Guide to Its Use in Advanced Medullary Thyroid Cancer
Gillian M. Keating
Katherine A. Lyseng-Williamson
James E. Frampton
BioDrugs, 2012, 26 (6) : 431 - 435
[27] Vandetanib: A novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer
Ton, GiangThy N.
Banaszynski, Megan E.
Kolesar, Jill M.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2013, 70 (10) : 849 - 855
[28] Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer
Helton Estrela Ramos
Fabio Hecht
Amandine Berdelou
Isabelle Borget
Sophie Leboulleux
Eric Baudin
Martin Schlumberger
Endocrine, 2021, 71 : 434 - 442
[29] Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer
Ramos, Helton Estrela
Hecht, Fabio
Berdelou, Amandine
Borget, Isabelle
Leboulleux, Sophie
Baudin, Eric
Schlumberger, Martin
ENDOCRINE, 2021, 71 (02) : 434 - 442
[30] Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
Robinson, Bruce G.
Paz-Ares, Luis
Krebs, Annetta
Vasselli, James
Haddad, Robert
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (06): : 2664 - 2671

← 1 2 3 4 5 →